netFormulary NHS
Cambridgeshire and Peterborough
Formulary
 Search
 Formulary Chapter 3: Respiratory system - Full Section
 Useful Links
Link   Asthma guidance (BTS / Sign 2016)
Link   Asthma inhaler devices (children under 5): NICE TA10
Link   Asthma inhaler devices (older children): NICE TA38:
Link   Bronchiectasis (non-CF) BTS guideline 2010
Link   COPD guideline: NICE CG101
Link   COVID-19: Use of high flow Oxygen therapy devices (including wall CPAP and high flow face mask or nasal oxygen) during the Coronavirus epidemic
Link   CUH Early supported discharge (ESD) for patients with COPD
Link   CUHFT: Respiratory: Asthma (adults)
Link   Inhalers for Asthma and COPD: Supply Issues June 2020
Link   National Patient Safety Alert 01/04/20: Interruption of high flow nasal oxygen during transfer
Link   Nebuliser compatibilities (UKMI Q&A)
Link   NHS England - Clinical guide for the management of palliative care in hospital during the coronavirus
Link   NICE - COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community [NG163]
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
03.01 Bronchodilators (0,1)
03.01.01 Adrenoceptor agonists (0,0)
03.01.01.01 Selective Beta2 agonists (5,4)
03.01.01.02 Other adrenoceptor agonists (0,2)
03.01.02 Antimuscarinic bronchodilators (5,1)
03.01.03 Theophylline (4,0)
03.01.04 Compound bronchodilator preparations (4,2)
03.01.05 Peak flow meters, inhaler devices and nebulisers (0,1)
Peak flow meters (1,6)
Drug delivery devices (3,9)
Nebulisers (0,0)
03.02 Corticosteroids (11,5)
03.02.01 Inhaled Corticosteroids (0,0)
03.02.02 Combination products (ICS+LABA) for asthma (0,0)
Low dose (0,0)
Moderate dose (0,0)
High dose (0,0)
03.02.03 Combination products (ICS+LABA) for COPD (0,0)
Triple Therapy products for COPD (1,1)
03.03 Cromoglicate, related therapy and leukotriene receptor antagonists (0,0)
03.03.01 Cromoglicate and related therapy (1,1)
03.03.02 Leukotriene receptor antagonists (1,0)
03.03.03 Phosphodiesterase type-4 inhibitors (1,0)
03.04 Antihistamines, hyposensitisation, and allergic emergencies (0,0)
03.04.01 Antihistamines (0,0)
Non-sedating antihistamines (3,5)
Sedating antihistamines (4,2)
03.04.02 Allergen Immunotherapy (3,1)
Monoclonal antibodies (4,0)
03.04.03 Allergic emergencies (0,0)
Anaphylaxis (3,1)
Angioedema (5,0)
03.05 Respiratory stimulants and pulmonary surfactants (0,0)
03.05.01 Respiratory stimulants (2,0)
03.05.02 Pulmonary surfactants (1,1)
03.06 Oxygen (0,0)
03.07 Mucolytics (6,2)
Dornase alfa (1,0)
Hypertonic Sodium Chloride (2,4)
Mannitol (1,0)
03.08 Aromatic inhalations (2,0)
03.09 Cough preparations (0,0)
03.09.01 Cough suppressants (3,2)
03.09.02 Expectorant and demulcent cough preparations (1,2)
03.10 Systemic nasal decongestants (1,1)
03.11 Antifibrotics (2,1)
netFormulary